Skip to content

FSME-TBE (Tick-Borne Encephalitis) Virus (Premium) Antigen BA112VS



  • Virion/Serion Immunologics Antigen for research use (RUO)
  • FSME-TBE (Tick-Borne Encephalitis) Virus (Premium) Antigen, recombinant
  • Suitable for detection of IgA, IgG & IgM antibodies in ELISA
  • Lot specific concentration, specified in mg/mL
  • 1 mg

Order now and receive on May 30, 2024

Calculate shipping price

Please fill in the fields below with the shipping destination details in order to calculate the shipping cost.

Weight1 lbs
Dimensions9 × 5 × 2 in

FSME/TBE (Tick-Borne Encephalitis) Virus

species reactivity

Tick-Borne Encephalitis Virus (TBE/FSME)



assay type

Indirect & quantitative

available size

1 mg

Research area
Infectious Disease
Store at -65°C or lower. Avoid repeated freeze-thaw cycles. 10 years from date of manufacture (under recommended storage conditions).
Associated products
FSME/TBE (Tick-Borne Encephalitis) Virus (Premium) Antigen (BA112VS)
FSME/TBE (Tick-Borne Encephalitis) Virus Antigen (BA112VSL)
Tick-Borne Encephalitis Virus IgG Control Serum (BC112G)
Tick-Borne Encephalitis Virus IgM Control Serum (BC112M)
Tick-Borne Encephalitis Virus IgG ELISA Kit (ESR112G)
Tick-Borne Encephalitis Virus IgM ELISA Kit (ESR112M)
target relevance
Tick-Borne Encephalitis Virus (FSME/TBE Virus)
Structure and strains
Tick-borne encephalitis virus (TBEV) is a positive-strand RNA virus associated with tick-borne encephalitis in the genus Flavivirus.
TBE Viruses can be transmitted to humans by infected ticks and may cause the so called tick-borne encephalitis (TBE). They belong to the human pathogenic species among the flaviviruses. Of particular note is the highly immunogenic envelope protein E, embedded in the surface of the virus. TBE Viruses are distributed throughout Europe and Asia. Depending upon their distribution, the three TBE Virus variants are referred to as the Central European, Siberian or Far Eastern subtype.

The majority of TBE Virus infections remain clinically asymptomatic. In 30% of cases, a biphasic course of disease starts with the onset of flu-like symptoms following an incubation period of 7 to 14 days. After a fever-free interval of one week, 10% of patients go on to develop encephalitis or meningoencephalitis, occasionally with long-lasting neurological symptoms. The majority of patients recover fully, even when the infection takes a severe course. However, there is a morbidity rate of around 1% for patients with CNS involvement. A naturally aquired infection usually leads to life-long immunity. In contrast, immunization results in limited immune protection and should be refreshed at regular intervals.
Detection and diagnosis
Cultivation of the TBE Virus is complex, time consuming and requires special safety precautions. Direct pathogen detection by RT-PCR is possible at the onset of disease, however, a negative result does not rule out a TBE Virus infection. As a consequence, the determination of pathogen-specific antibodies by ELISA is recommended for laboratory confirmation of TBE Virus infections. The combined demonstration of IgG and IgM antibodies directed against TBE Virus, a significant increase in antibody activity by the analysis of serum pairs or the detection of intrathecally synthesized IgG or IgM antibodies serve to confirm an infection.



Published literature highly relevant to the biological target of this product and referencing this antibody or clone are retrieved from PubMed database provided by The United States National Library of Medicine at the National Institutes of Health.



relevant to this product
BA112VS protocol


Product data sheet


There are no reviews yet.

Be the first to review “FSME-TBE (Tick-Borne Encephalitis) Virus (Premium) Antigen BA112VS”